Talis Biomedical (TLIS) Annual Balance Sheets

Annual · GAAP · USD millions
Access TLIS quarterly Balance Sheets →
A period-by-period view of the balance sheet from Talis Biomedical to helps clarify how Dec 31 2023's financial structure has changed over time.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2023)
(Dec 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent76.73
Cash & Short-term Investments76.00
Accounts receivable0.05
Grants Receivable, Current0.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.90
Total Current Assets77.68
Equipment/Property/Plant Net3.03
Other Assets, Noncurrent2.00
Operating Lease Right Of Use Asset12.42
Total Assets94.67
Liabilities
Accounts Payable, Current AC1.34
Accrued Liabilities, Current AC0.72
Other Liabilities, Current6.72
Total Current Liabilities8.77
Total Long-term Debt0.00
Other liabilities, Noncurrent16.79
OperatingLeaseLiabilityNoncurrent16.79
Accrued Compensation Current3.84
Operating Lease Liability Current2.88
Total Liabilities25.56
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock609.07
Retained Earnings / Accumulated Deficit-539.96
Other Equity0.00
Common Stockholder's Equity69.11
Preferred Stockholder's Equity0.00
Total Stockholder's Equity69.12
Liabilities & Stockholder's Equity94.67
4 historic quarters locked

Sign in to unlock the full Talis Biomedical balance sheet history.

About Talis Biomedical Corp Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-037648

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.